4-(3-(trifluoromethyl)-3H-diazirin-3-yl)aniline

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-(trifluoromethyl)-3H-diazirin-3-yl)aniline
• 英文别名: 4-(3-(Trifluoromethyl)-3H-diazirin-3-yl)aniline；4-[3-(trifluoromethyl)diazirin-3-yl]aniline
• 化学式: C₈H₆F₃N₃
• 分子量: 201.151
• InChiKey: KBYVARJFNZZBBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(3-(trifluoromethyl)-3H-diazirin-3-yl)aniline 在 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.5h， 生成 (R)-2-amino-N-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)pent-4-ynamide
  参考文献：
  名称：

  Divergent Synthesis of Photoaffinity Probe Candidates by Click Reactions of Azido-Substituted Aryltrifluoromethyldiazirines

  摘要：

  DOI：

  10.3987/com-18-s(f)76
• 作为产物：
  描述：

  2,2,2,4'-四氟苯乙酮 在 吡啶 、 lithium aluminium tetrahydride 、 sodium azide 、 盐酸羟胺 、 氨 、 碘 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 30.0h， 生成 4-(3-(trifluoromethyl)-3H-diazirin-3-yl)aniline
  参考文献：
  名称：

  DOT1L抑制剂衍生的基于小分子亲和力的探针的原位蛋白质组分析和生物成像应用

  摘要：

  DOT1L是使赖氨酸79（H3K79）上的组蛋白H3甲基化的唯一蛋白质甲基转移酶，并且是一种有前途的抗癌药物。DOT1L的小分子抑制剂（例如FED1）是潜在的抗癌药，是研究DOT1L在人类疾病中的生物学作用的有用工具。FED1对DOT1L表现出优异的体外抑制活性，但其细胞作用相对较差。在这项研究中，我们设计并合成了具有光反应性和“可点击”亲和力的探针（AfBPs）P1和P2，它们是FED1的细胞渗透性和结构类似物。在体外和活的哺乳动物细胞（原位）中广泛研究了这两种探针对DOT1L蛋白的结合和抑制作用。随后在活细胞成像实验中研究了探针的细胞摄取和亚细胞定位特性，我们的结果表明，尽管P1和P2都容易进入哺乳动物细胞，但大多数不能到达细胞核，功能DOT1L驻留。这为FED1的细胞活性差提供了一个合理的解释。最后，使用P1 / P2进行大规模基于细胞的蛋白质组分析，然后进行定量LC-MS / MS

  DOI：

  10.1002/chem.201600259

文献信息

• [EN] BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVÉS DE BENZÈNESULFONAMIDE EN TANT QUE MODULATEURS TRAP1 ET UTILISATIONS ASSOCIÉES
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188880A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了Formula (I)的化合物及其药用盐、溶剂化合物、水合物、多晶形态、共晶体、互变异构体、立体异构体、同位素标记化合物和其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能在PTEN诱导激酶1（"PINK1"）功能丧失的情况下恢复活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，并/或减少活性氧自由基的产生。所提供的化合物还可能对α-突触核蛋白等聚集或错误折叠的蛋白进行重新折叠或溶解。本公开还提供了包含所提供化合物的药物组合物；包含所提供化合物或药物组合物的试剂盒；以及使用所提供化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。
• Photoactive bioadhesive compositions
  申请人：Nanyang Technological University

  公开号：US10005936B2

  公开（公告）日：2018-06-26

  A novel diazirine-based biocompatible polymer that can be used as on-demand or tunable bioadhesive and applied across various clinically important surfaces. The biocompatible polymer comprises a single strand of repeating units and up to 5,000 photoreactive diazirine groups covalently attached to it. A bioadhesive composition comprises the polymer of the present invention and suitable solvents, surfactants, stabilizers, fillers and other additives. The composition may additionally contain metallic particles of size less than 50 micron made of rare earth elements and has UV or NIR transparency less than 1 optical density unit per 1 centimeter. The poly-diazirine surface grafted thin films can be used for minimally invasive surgeries.

  一种新型重氮基生物相容性聚合物，可用作按需或可调生物粘合剂，应用于各种重要的临床表面。这种生物相容性聚合物由单股重复单元和多达 5,000 个共价连接的光活性重氮氨酸基团组成。生物粘合剂组合物由本发明的聚合物和合适的溶剂、表面活性剂、稳定剂、填料和其他添加剂组成。此外，该组合物还可能含有由稀土元素制成的尺寸小于 50 微米的金属颗粒，其紫外线或近红外透明度小于每 1 厘米 1 个光密度单位。聚二氮杂环胺表面接枝薄膜可用于微创手术。
• SUGAR ALCOHOL-BASED CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF
  申请人：CellMosaic, Inc.

  公开号：EP2734238B1

  公开（公告）日：2020-02-19
• New Photoactive Bioadhesive Compositions
  申请人：NANYANG TECHNOLOGICAL UNIVERSITY

  公开号：US20150315434A1

  公开（公告）日：2015-11-05

  A novel diazirine-based biocompatible polymer that can be used as on-demand or tunable bioadhesive and applied across various clinically important surfaces. The biocompatible polymer comprises a single strand of repeating units and up to 5,000 photoreactive diazirine groups covalently attached to it. A bioadhesive composition comprises the polymer of the present invention and suitable solvents, surfactants, stabilizers, fillers and other additives. The composition may additionally contain metallic particles of size less than 50 micron made of rare earth elements and has UV or NIR transparency less than 1 optical density unit per 1 centimetre. The poly-diazirine surface grafted thin films can be used for minimally invasive surgeries.
• NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF
  申请人：CellMosaic, Inc.

  公开号：US20170065726A1

  公开（公告）日：2017-03-09

  The invention provides novel chemical entities based on sugar alcohols. These new chemical entities are biocompatible and biodegradable. The molecules can be made in a single and pure form. The molecular weights of these molecules range from small (<1000 Da) to large (1000-120,000 Da). The sugar alcohol-based molecules can have functional groups throughout the molecule for crosslinking compounds, such as the preparation of antibody-drug conjugates, or to facilitate the delivery of therapeutic proteins, peptides, siRNA, and chemotherapeutic drugs. Also provided are new conjugate entities prepared through sugar alcohol molecules. Methods of synthesizing sugar alcohol-based molecules and conjugates are also within the scope of the invention.